Biomarkers for Typing Allograft Recipients
AssigneesVito NV, Medizinische Hochschule Hannover, Katholieke Universiteit Leuven, Institut National De La Sante Et De La Recherche Medicale (Inserm), APHP - Assistance Publique - Hôpitaux Paris, University Hospital Center of Limoges
InventorsInge Mertens, Hanny Willems, Maarten Naessens, Pierre Marquet, Dany Anglicheau, Marie Essig, Wilfried Gwinner
Life of this patent
Estimating the term…
Abstract
The invention relates to biomarkers for typing or classifying allograft recipients as belonging to a transplant rejection group associated with antibody-mediated rejection (ABMR). The invention also provides for the treatment of typed allograft recipients suffering from antibody-mediated rejection by administration of an appropriate therapeutic agent.
Claims20
A method for typing an allograft recipient for the presence or absence of an antibody mediated rejection (ABMR), comprising the steps of
- measuring in a sample comprising proteins from an allograft recipient a protein level for at least two genes selected from the group consisting of TF, SERPINA1, APOA4, AFM, AZGP1, ORM1, ORM2, C3, A1BG, SERPINC1, LRG1, IGHA1, IGHG4, TFAP2C, HPX, A2M, CARD6, SERPINA7, CCDC73, CYSTM1 and APOA1;
- comparing said measured protein level to a reference protein level for said at least two genes;
- and
- typing said allograft recipient for the presence or absence of an ABMR on the basis of the comparison of the measured protein level and the reference protein level.
A method for assigning an allograft recipient to an ABMR group or a non-ABMR group comprising the steps of:
- measuring in a sample comprising proteins from an allograft recipient suffering, or at risk of suffering, from transplant rejection a protein level for at least two genes selected from the group consisting of TF, SERPINA1, APOA4, AFM, AZGP1, ORM1, ORM2, C3, A1BG, SERPINC1, LRG1, IGHA1, IGHG4, TFAP2C, HPX, A2M, CARD6, SERPINA7, CCDC73, CYSTM1 and APOA1;
- comparing said measured protein level to a reference protein level for said at least two genes;
- and
- assigning said allograft recipient to said ABMR group or to said non-ABMR group on the basis of the comparison of the measured protein level and the reference protein level.
Dependencies are inferred from the claim text.